MTRNR2L1

Across TCGA pan-cancer cohorts, MTRNR2L1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MTRNR2L1 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MTRNR2L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTRNR2L1 expression acts as an unfavorable survival marker.

CHOL and SARC are the cancer types where MTRNR2L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
SARC	OS	Median	All	0.127	0.860	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MTRNR2L1–CHOL (DFS)

Open the CHOL breakdown →